Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT00730470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.
Study identification
- NCT ID
- NCT00730470
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- U3 Pharma GmbH
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- U3-1287 (AMG888) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2008
- Primary completion
- Jun 30, 2010
- Completion
- Jun 30, 2010
- Last update posted
- Jul 28, 2010
2008 – 2010
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dana Faber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Memorial Sloan-Kettering Cancer Centre | New York | New York | 10065 | — |
| Vanderbilt Ingram cancer Centre | Nashville | Tennessee | 37232 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00730470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2010 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00730470 live on ClinicalTrials.gov.